It gives a roundup of the latest news on research into muscle-wasting conditions as well as an update on latest information on potential drug license applications and clinical trials.
In this issue, you can read about the use of harmless viruses (AAVs) for the treatment of muscle-wasting conditions such as Duchenne muscular dystrophy and spinal muscular atrophy. There’s also a report from the ninth UK Neuromuscular Translational Research Conference, which provides a platform for scientists and clinicians in the neuromuscular field to discuss their latest findings.
Read Target Research 2016 online.
Friends of MDUK receive our Campaign newsletter, Target MD, a copy of our annual Impact Report and other benefits – for only £15 a year by Direct Debit. Visit the Friends of MDUK page to find out more and join today!